

Consistently
delivering access to
**PrFulvestrant
Injection**

THIS PRODUCT
IS COVERED BY
Continium™
Patient Support Program
SEE BACK FOR DETAILS



- > Similar injection device (syringe and needle)
- > Available in pack of two pre-filled syringes and two needles
- > Preservative free

A generic equivalent to ^{Pr}Faslodex*

*Registered trademark owned by its respective registrant.

Please consult the Product Monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Drug Information at 1-800-343-8839, ext. 4636.


SANDOZ A Novartis
Division

Sandoz Canada Inc. 110, rue de Lauzon, Boucherville (Québec) J4B 1E6
www.sandoz.ca

18-12-MKT002 exp 2021-02

PrFulvestrant Injection

A generic equivalent to PrFaslodex*

Appearance	Strength	Format	UPC	DIN
	250 mg/5 mL (50 mg/mL)	Two pre-filled syringes of 5 mL each	0 5751321955 9	02483610

Nonmedicinal ingredients (in alphabetical order):
Benzyl alcohol, benzyl benzoate, castor oil, and ethanol 96%.



Support you can trust

What is Sandoz Continuum™?

It is a free, simple, and personalized patient support program for PrFulvestrant Injection.

What does the program offer?

Our experienced team of patient access specialists provide:

- Financial assistance
- Reimbursement navigation

Simple patient enrolment

The Sandoz Continuum™ enrolment form is available by calling us at 1-888-6-SANDOZ (726369), or online at sandoz.ca/en/psp.



For any questions, please contact Sandoz Continuum™ at 1-888-6-SANDOZ (726369).

*Registered trademark owned by its respective registrant.

PrFulvestrant Injection (fulvestrant) is indicated for the treatment of estrogen receptor-positive, human epidermal growth receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, and is also indicated for the hormonal treatment of locally advanced or metastatic breast cancer in postmenopausal women, regardless of age, who have disease progression following prior anti-estrogen therapy.

Please consult the product monograph available at sandoz.ca/en/Generics or obtain a copy by calling Sandoz Drug Information at 1-800-343-8839, ext. 4636.